<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01758250</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00039256</org_study_id>
    <nct_id>NCT01758250</nct_id>
  </id_info>
  <brief_title>Microvascular and Fibrosis Imaging Study</brief_title>
  <official_title>Mechanistic Study: Non-Invasive Cutaneous Microvascular and Fibrosis Imaging of Patients With Systemic Sclerosis, Sickle Cell Disease and Chronic Graft-Versus-Host Disease (GVHD) Compared to Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, Laser Doppler Flowmetry (LDF), Laser Doppler Imaging (LDI), Orthogonal&#xD;
      Polarization Spectral Imaging (OPSI), Nail fold video capillaroscopy (NVC) and Optical&#xD;
      Coherence Tomography (OCT) will be used to assess differences in microvascular function and&#xD;
      density of oral mucosa and skin in subjects with 1) autoimmune diseases with cutaneous&#xD;
      involvement: systemic sclerosis (SSc), morphea, dermatomyositis, cutaneous lupus and&#xD;
      vasculitis, 2) sickle cell disease (SCD) and 3) chronic graft-versus-host disease (GVHD)&#xD;
      compared to healthy subjects. The microvascular changes will be compared to overall treatment&#xD;
      response in patients with scleroderma and chronic GVHD as assessments will be made before and&#xD;
      after the patients start treatment for their diseases and determine if these imaging&#xD;
      techniques provide valuable and reproducible data when assessing a patient's response to&#xD;
      treatment for those diseases. In addition, the application of Acoustic Radiation Force&#xD;
      Impulse (ARFI) in determining cutaneous thickness in patients with SSc, GVHD and morphea will&#xD;
      be evaluated.&#xD;
&#xD;
      The investigators hypothesize that the vascular and dermal structures are altered in patients&#xD;
      with autoimmune disease, SCD and chronic GVHD. In addition, they hypothesize that imaging&#xD;
      modalities such as LDF, LDI, OCT, NVC, OPSI and ARFI can quantify such structural alterations&#xD;
      and can be used to 1) detect early disease activity, 2) quantify and assess response to&#xD;
      therapy and 3) quantify and correlate with overall disease activity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2013</start_date>
  <completion_date type="Actual">February 2018</completion_date>
  <primary_completion_date type="Actual">February 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Microvascular density in oral mucosa and skin</measure>
    <time_frame>over 24 months</time_frame>
    <description>Microvascular density as evaluated using LDF, LDI, OPSI, OCT, NVC and AFRI, will be compared between subjects with and without disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Microvascular Perfusion in oral mucosa and skin</measure>
    <time_frame>over 24 months</time_frame>
    <description>Microvascular perfusion as evaluated using LDF, LDI, OPSI, OCT, NVC, and AFRI, will be compared between subjects with and without disease.</description>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Actual">63</enrollment>
  <condition>Autoimmune Diseases</condition>
  <condition>Sickle Cell Disease</condition>
  <condition>Chronic Graft Versus Host Disease</condition>
  <arm_group>
    <arm_group_label>Systemic Sclerosis</arm_group_label>
    <description>Patients with SSc will have imaging studies performed at baseline and at 3, 6, 9, 12, 15, 18, 21 and 24 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GVHD</arm_group_label>
    <description>Patients with GVHD will have imaging studies performed at baseline and at 3, 6, 9, 12, 18 and 24 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Undergoing HSCT</arm_group_label>
    <description>Patients who are about to undergo HSCT will have imaging studies performed at 1 week pre-transplantation, day 40 and 80 post transplantation and at 3 months, 6 months, 12 months 18 months and 24 months post-transplant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Healthy Controls and Controls with hematologic and solid organ malignancies and dermatitis will have imaging studies performed at a single point in time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sickle cell disease</arm_group_label>
    <description>Patients with SCD will have imaging studies performed at baseline and at 3, 6, 9, 12, 15, 18, 21 and 24 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cutaneous fibrosing disorder</arm_group_label>
    <description>Patients with active cutaneous fibrosing disorder will have imaging studies performed at a single point in time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Acoustic Radiation Force Impulse (ARFI)</intervention_name>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Cutaneous fibrosing disorder</arm_group_label>
    <arm_group_label>GVHD</arm_group_label>
    <arm_group_label>Sickle cell disease</arm_group_label>
    <arm_group_label>Systemic Sclerosis</arm_group_label>
    <arm_group_label>Undergoing HSCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laser Doppler Flowmetry (LDF)</intervention_name>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Cutaneous fibrosing disorder</arm_group_label>
    <arm_group_label>GVHD</arm_group_label>
    <arm_group_label>Sickle cell disease</arm_group_label>
    <arm_group_label>Systemic Sclerosis</arm_group_label>
    <arm_group_label>Undergoing HSCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laser Doppler Perfusion Imaging (LDI)</intervention_name>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Cutaneous fibrosing disorder</arm_group_label>
    <arm_group_label>GVHD</arm_group_label>
    <arm_group_label>Sickle cell disease</arm_group_label>
    <arm_group_label>Systemic Sclerosis</arm_group_label>
    <arm_group_label>Undergoing HSCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Optical Coherence Tomography (OCT)</intervention_name>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Cutaneous fibrosing disorder</arm_group_label>
    <arm_group_label>GVHD</arm_group_label>
    <arm_group_label>Sickle cell disease</arm_group_label>
    <arm_group_label>Systemic Sclerosis</arm_group_label>
    <arm_group_label>Undergoing HSCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Orthogonal Polarization Spectral Imaging (OPSI)</intervention_name>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Cutaneous fibrosing disorder</arm_group_label>
    <arm_group_label>GVHD</arm_group_label>
    <arm_group_label>Sickle cell disease</arm_group_label>
    <arm_group_label>Systemic Sclerosis</arm_group_label>
    <arm_group_label>Undergoing HSCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Nail fold video capillaroscopy (NVC)</intervention_name>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Cutaneous fibrosing disorder</arm_group_label>
    <arm_group_label>GVHD</arm_group_label>
    <arm_group_label>Sickle cell disease</arm_group_label>
    <arm_group_label>Systemic Sclerosis</arm_group_label>
    <arm_group_label>Undergoing HSCT</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient population at Duke University Medical Center and healthy controls&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects above the age of 18 who are capable of giving informed consent with one of&#xD;
             the following conditions: Scleroderma, Graft vs Host Disease, Sickle Cell Disease,&#xD;
             Morphea, Connective Tissue Disease with cutaneous manifestations: cutaneous lupus,&#xD;
             dermatomyositis, vasculitis, patients who are undergoing HSCT, or patients with a&#xD;
             diagnosis of hematologic and non-hematologic malignancies without GVHD&#xD;
&#xD;
          -  Control patients include normal healthy controls above the age of 18 who are capable&#xD;
             of giving informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who experience discomfort, will be prone to experience discomfort or cannot&#xD;
             tolerate the position required for the imaging studies.&#xD;
&#xD;
          -  Subjects unable to provide informed consent.&#xD;
&#xD;
          -  Smokers, patients unable to tolerate caffeine avoidance for the day of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith Sullivan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adela Cardones, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 26, 2012</study_first_submitted>
  <study_first_submitted_qc>December 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2013</study_first_posted>
  <last_update_submitted>September 10, 2020</last_update_submitted>
  <last_update_submitted_qc>September 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autoimmune diseases with cutaneous involvement</keyword>
  <keyword>Systemic sclerosis</keyword>
  <keyword>Scleroderma</keyword>
  <keyword>Morphea</keyword>
  <keyword>Dermatomyositis</keyword>
  <keyword>Cutaneous lupus</keyword>
  <keyword>Vasculitis</keyword>
  <keyword>Sickle Cell Disease</keyword>
  <keyword>Graft versus Host Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

